Press Release
Press Release
-
INNORNA’s Covid mRNA Vaccine Approved by New Zealand for Phase I Clinical Trial
2022-12-20Shenzhen, December 20, 2022—INNORNA announced that New Zealand Medicines and Medical Devices Safety Administration (MEDSAFE) approved a phase I clinical trial for its COVID-19 vaccine to conduct Head to Head comparative study against mRNA vaccines on the market in Europe and the United States.Learn More + -
InnoRNA and BeiGene Announce Strategic Research Collaboration to Jointly Discover Novel mRNA Therapies
2022-07-06BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programsLearn More + -
INNORNA raises USD 120 million in Series B funding
2022-03-28Shenzhen, March 28, 2022 - Shenzhen INNORNA Biotechnology Co., Ltd. (hereinafter referred to as “INNORNA”) officially announced that it has raised USD 120 million in Series B funding. CDH Investment and HHF Capital were the lead-investors and E Fund Capital and Blue Ocean Capital Group were co-invLearn More + -
INNORNA raises hundreds of millions RMB in Series A funding
2021-07-28Shenzhen, July 28, 2021- Shenzhen INNORNA Biotechnology Co., Ltd. (hereinafter referred to as “INNORNA”) officially announced that it has raised hundreds of millions RMB in Series A funding in the first quarter of the year, leading in funding size among competitors in the same track and same serieLearn More +